Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Regen Biopharma Inc (OP: RGBP )

0.0593 USD UNCHANGED
Streaming Delayed Price Updated: 4:02 PM EDT, Apr 12, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0593
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0593
Today's Range 0.0593 - 0.0593
52wk Range 0.0001 - 0.0819
Shares Outstanding 151,327,211
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Regen BioPharma, Inc. Discovers Fundamental Role of NR2F6 in Production of Malignant Blood Vessels
Laboratory Data and Patent Filing Supports Possible Treatments for Wet Macular Degeneration and Cancer 
From PR Newswire
Regen BioPharma Successfully Treats Rheumatoid Arthritis Using Cannabidiol (CBD) Based Immune Modulatory Treatments
Company Develops Novel T Regulatory Cell Activating Approach Potentially Useful for Diverse Autoimmune and Inflammatory Diseases 
From PR Newswire

Performance

YTD
+7312.50%
+7312.50%
1 Month
+3853.33%
+3853.33%
3 Month
+7312.50%
+7312.50%
6 Month
+11760.00%
+11760.00%
1 Year
+59200.00%
+59200.00%

More News

Read More
Regen BioPharma Discovers Potential New Way to Improve Outcomes from Cancer Surgery Using Combination of Cannabidiol and NR2F6 Inhibition
From PR Newswire
Regen BioPharma Inc. Files Immuno-Oncology Patent Application on Synergy of Cannabidiol With NR2F6 Modulation
From PR Newswire
Regen BioPharma, Inc. Responds to Fake News Release
From PR Newswire
Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease
From PR Newswire
Regen BioPharma, Inc. Reports Additional New NR2F6 Small Molecule Inhibitors
From PR Newswire
Increasing Number of Cancer Cases to Fuel the Global Cancer Immunotherapy Market Growth
From PR Newswire
Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies
From PR Newswire
Cancer Immunotherapy Treatment Market on the Rise as R&D Increases
From PR Newswire
Regen BioPharma, Inc. Reports Activation of Immune Cells by Its NR2F6 Small Molecule Inhibitors
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.